Postoperative Use of Bevacizumab as an Antifibrotic Agent in Glaucoma Filtration Surgery in the Rabbit
Postoperative Use of Bevacizumab as an Antifibrotic Agent in Glaucoma Filtration Surgery in the Rabbit
复制标题
DOI：
10.1167/iovs.08-2441
复制
发表时间：
2009-07-01
影响因子：
4.4
通讯作者：
Eliott, Dean
中科院分区：
文献类型：
--
作者：
Memarzadeh, Farnaz;Varma, Rohit;Eliott, Dean
目的.评价贝伐单抗在兔小梁切除术后的抗纤维化作用。42只家兔接受小梁切除术，并随机分配接受7次贝伐珠单抗（1.25 mg，25 mg/mL）、5-氟尿嘧啶（5-FU; 5 mg，50 mg/mL）或平衡盐溶液（BSS; 0.1 mL，对照）结膜下注射的术后疗程。在30天的时间内评价了滤过泡的存活率和特征。在术后（PD）第10天、PD 20天和PD 30天处死动物。对手术眼进行组织学和免疫组化，以评估和分级各组中瘢痕形成和纤维化的量。贝伐单抗显著改善了该模型中滤过手术的结局。与5-FU和对照组相比，贝伐单抗延长了滤过泡存活时间（分别为16.0 +/- 1.3天vs. 6.9 +/- 0.6和7.4 +/- 0.85天; P < 0.001）。贝伐珠单抗治疗组的滤过泡明显大于对照组和5-FU治疗组（P < 0.05）。组织学分析显示，在PD 10和PD 20时，接受贝伐单抗治疗的眼睛在显微镜水平上的术后瘢痕形成显著较少（P=0.009）。兔模型中术后结膜下注射贝伐单抗与小梁切除术滤过泡存活率改善相关。贝伐单抗可能是一种有用的药物，以提高成功率和限制小梁切除术后瘢痕组织的形成。（Invest Ophthalmol维斯科学。2009;50：3233-3237）DOI：10.1167/iovs.08-2441
PURPOSE. To evaluate the efficacy of bevacizumab as an antifibrotic agent after trabeculectomy in rabbits.METHODS. Forty-two rabbits underwent trabeculectomy and were randomly assigned to receive a postoperative course of seven subconjunctival injections of bevacizumab (1.25 mg, 25 mg/mL), 5-fluorouracil (5-FU; 5 mg, 50 mg/mL), or balanced salt solution (BSS; 0.1 mL, control). Bleb survival and characteristics were evaluated over a 30-day period. The animals were killed on postoperative day (PD) 10, PD20, and PD30. Histology and immunohistochemistry of the surgical eyes was performed to evaluate and grade the amount of scarring and fibrosis in each group.RESULTS. Bevacizumab significantly improved the outcome of filtration surgery in this model. Bevacizumab prolonged bleb survival compared with the 5-FU and control groups (16.0 +/- 1.3 days vs. 6.9 +/- 0.6 and 7.4 +/- 0.85 days, respectively; P < 0.001). Bevacizumab-treated eyes had significantly larger and higher blebs than the control and 5-FU-treated groups (P < 0.05). Histologic analysis revealed that eyes treated with bevacizumab had significantly less postoperative scarring at the microscopic level at PD10 and PD20 (P=0.009).CONCLUSIONS. Postoperative subconjunctival injection of bevacizumab is associated with improved trabeculectomy bleb survival in the rabbit model. Bevacizumab may be a useful agent for improving success and limiting scar tissue formation after trabeculectomy. (Invest Ophthalmol Vis Sci. 2009;50: 3233-3237) DOI: 10.1167/iovs.08-2441